Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Intangibles (2016 - 2025)

Historic Change in Intangibles for Ani Pharmaceuticals (ANIP) over the last 13 years, with Q3 2025 value amounting to $60000.0.

  • Ani Pharmaceuticals' Change in Intangibles fell 9049.13% to $60000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year increase of 55196.42%. This contributed to the annual value of $717000.0 for FY2024, which is 9256.46% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its Change in Intangibles stood at $60000.0 for Q3 2025, which was down 9049.13% from $2.9 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Change in Intangibles peaked at $21.0 million during Q2 2021, and registered a low of $4000.0 during Q4 2022.
  • In the last 5 years, Ani Pharmaceuticals' Change in Intangibles had a median value of $430000.0 in 2022 and averaged $3.7 million.
  • Its Change in Intangibles has fluctuated over the past 5 years, first plummeted by 9993.04% in 2021, then surged by 6240000.0% in 2023.
  • Over the past 5 years, Ani Pharmaceuticals' Change in Intangibles (Quarter) stood at $12000.0 in 2021, then tumbled by 66.67% to $4000.0 in 2022, then surged by 62400.0% to $2.5 million in 2023, then tumbled by 96.56% to $86000.0 in 2024, then crashed by 30.23% to $60000.0 in 2025.
  • Its Change in Intangibles stands at $60000.0 for Q3 2025, versus $2.9 million for Q2 2025 and $17.4 million for Q1 2025.